Janssen and B-MS in collaboration over immuno-oncology in lung cancer

26 July 2016

Janssen Biotech, a subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ), has announced a collaboration with pharma major Bristol-Myers Squibb (NYSE: BMY) to evaluate the combination of two immuno-oncology compounds in non-small cell lung cancer (NSCLC).

A Phase II trial will test the tolerability and clinical activity of the combination of Janssen's investigational immunotherapy JNJ-64041757 and B-MS’ PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in NSCLC patients.

JNJ-64041757 is an antigen-presentation therapeutic which Janssen licensed from USA-based Aduro Biotech (Nasdaq: ADRO) in 2014, which is currently in Phase I development. It is designed to induce the local recruitment and activation of innate and adaptive effector cells and expansion of mesothelin-specific T cells.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK